Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations

• US 20060128726A1
• Filed: 11/21/2005
• Published: 06/15/2006
• Est. Priority Date: 11/24/2004
• Status: Abandoned Application

• Current Assignee: Bristol-Myers Squibb Company
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Lai, Chiajen, DiMarco, John D., Gougoutas, Jack Z., Soundararajan, Nachimuthu, Yan, Lin, Burton, Lori S., Raghavan, Krishnaswamy Srinivas, Yin, Xiaotian, Gandhi, Rajesh Babulal, Zhou, Yuji Simon, Nguyen, Nina, Wang, Xuebao, West, Ronald C., Ying, Weiming
• Application Number:
  US11/283,651
• Publication Number:
  US 20060128726A1
• Time in Patent Office: Days
• US Class Current: 514/259.300
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

A process is provided for preparing novel crystalline forms, namely selectively and consistently preparing the H2-1 dihydrate crystalline form, the H2-2 dihydrate crystalline form, the N-3 anhydrate crystalline form and the MTBE solvate crystalline form of the IKur compound (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine. The process includes preparation of the H2-1 and H2-2 forms which are used in preparing the N-3 anhydrate form which is particularly stable and has suitable flow properties and desired particle size. Novel H2-1 dihydrate and H2-2 dihydrate forms, the N-3 anhydrate form and the MTBE solvate form of the above IKur compound, pharmaceutical compositions containing such novel forms and a method for preventing or treating arrhythmias including atrial fibrillation and IKur related conditions employing such novel forms are also provided.

Claims

1. a) The H2-1 dihydrate crystalline form of the free base of the structure

b) the H2-2 dihydrate crystalline form of the free base of the structure as defined above;

c) the N-3 anhydrate crystalline form of the free base of the structure as defined above;

or

d) the MTBE solvate of the free base of the solvate as defined above.

2. The H2-1 dihydrate crystalline form of the free base of the structure

as defined in claim 1, as characterized by the simulated and observed powder x-ray diffraction patterns shown in FIG. 1 or in the observed pattern, by the first 5 major peaks at 12.67 (±

0.1)°

, 14.18 (±

0.1)°

, 23.99 (±

0.1)°

, 24.42 (±

0.1)°

, and 30.70 (±

0.1)°

two theta, as shown in FIG. 1, and by the thermograms shown in FIGS. 2 and 2A.

Single Crystal X-Ray Diffraction Measurement;

H2-1 Dihydrate Refcode;

394136H2 Crystal Form;

BMS;

394136 H2-1 Accession No.;

1547 X-ray Notebook No.;

46521-140 Chemist Notebook;

47655-173-23 Chemical formula;

C₂₄H₂₁N₄OFCl₂.2H₂O Crystallization solvent;

MeCN/water a;

9.760(2) Å

α

;

97.82(2)°

Crystal description;

colorless prisms b;

15.119(4) Å

β

;

115.69(2)°

Melting point;

(t)85, (glass)108-113, 130-143°

C. c;

9.439(3) Å

γ

;

99.88(2)°

Measured indices;

±

h, ±

k, ±

l V;

1201(1) Å

³ Z;

2 Temperature (°

C.);

−

43 Space group;

P1 V/Z;

600 Å

³ (2θ

)max, °

;

130 D_calc (g-cm<sup>−

3</sup>);

1.403 No. of independent reflections;

5592 Absorption coefficient, cm<sup>−

1</sup>;

28.2 No. of observed reflections (I ≧

3σ

);

5393 Molecular volume (V_m);

832 No. refined variables;

621 Molecular Surface Area;

880 R;

0.082 Renan;

0.092 Packing coefficient (Z ·

V_m/V_c);

0.69 Rw;

0.10 Rw enan;

0.12 Disorder;

Dichlorophenyl disordered Avg. errors (C, N, O);

0.01 Å

0.6°

(4;

1) Solvent;

2 water sites Occupancy;

1.0 chlathrate

3. The H2-2 dihydrate crystalline form of the free base of the structure

as defined in claim 1, as characterized by the simulated and observed powder x-ray diffraction patterns or in the observed pattern, by the first 5 major peaks:

13.72 (±

0.1)°

, 18.35 (±

0.1)°

, 20.48 (±

0.1)°

, 23.78 (±

0.1)°

, and 26.63 (±

0.1)°

two theta, as shown in FIG. 3, and by the thermograms shown in FIGS. 4 and 4A.

Single Crystal X-ray Diffraction Measurement H2-2 Dihydrate Refcode;

394136HB BMS;

394136 Crystal Form;

H2-2 Accession No.;

1646 X-ray Notebook No.;

50572-004 Chemist Notebook Chemical formula;

C₂₄H₂₁N₄OFCl₂.2H₂O Crystallization solvent;

EtOH/H₂O/L-Pro a;

9.7085(3) Å

α

;

90°

Crystal description;

tiny twinned colorless prisms b;

28.913(1) Å

β

;

122.355(2)°

Melting point;

(glass)105-107, 133-140°

C. c;

10.2911 Å

γ

;

90°

Measured indices;

+h, +k, ±

l V;

2440.2(1) Å

3 Z;

4 Temperature (°

C.);

25 Space group;

P21 V/Z;

610 Å

3 (2θ

.max, °

;

81 Dcalc (g-cm−

3);

1.381 No. of independent reflections;

2520 Absorption coefficient, cm−

1;

27.8 No. of observed reflections (I >

3σ

);

2344 Molecular volume (Vm);

840 No. refined variables;

613 Molecular Surface Area;

977 R;

0.042 Renan;

0.053 Packing coefficient (Z ·

Vm/Vc);

0.69 Rw;

0.051 Rw enan;

0.067 Disorder;

Avg. errors (C, N, O);

0.02 Å

1.5°

Solvent;

2 water sites Occupancy;

1.0 clathrate

4. The N-3 anhydrate crystalline form of the free base of the structure

as defined in claim 1, as characterized by the simulated and observed powder x-ray diffraction patterns, or in the observed pattern, by the first 5 major peaks:

12.63 (±

0.1)°

, 17.14 (±

0.1)°

, 21.74 (±

0.1)°

, 22.76 (±

0.1)°

, and 27.11 (±

0.1)°

two theta, as shown in FIG. 5, and by the thermograms shown in FIGS. 6 and 6A.

5. The MTBE solvate crystalline form of the free base of the structure

as defined in claim 1, as characterized by the observed powder x-ray diffraction patterns or the first 5 major peaks:

16.51 (±

0.1)°

, 17.11 (±

0.1)°

, 18.08 (±

0.1)°

, 21.10 (±

0.1)°

, and 23.87 (±

0.1)°

two theta, as shown in FIGS. 8 and 8A, and by the thermograms shown in FIGS. 9 and 9A.

6. A process for preparing the N-3 anhydrate crystalline form of the IKur compound of the structure

as defined in claim 4, which comprises:

a) providing the H2-2 dihydrate crystalline form of the IKur compound;

b) treating H2-2 dihydrate crystalline form with ethyl alcohol;

c) optionally seeding the reaction mixture from step b) with N-3 anhydrate crystalline form of the IKur compound to form a reaction slurry;

d) heating the slurry from step c) at an elevated temperature up to about 50°

C.; and

e) drying the resulting product and recovering N-3 anhydrate crystals of the IKur compound.

7. The process as defined in claim 6 wherein the reaction mixture from step b) is treated with seeds of N-3 anhydrate crystals of the IKur compound.

8. The process as defined in claim 6 wherein the reaction mixture from step b) or step c) is heated at a temperature within the range from about 35 to about 50°

C. for a period within the range from about 0.5 to about 20 hours, and the reaction mixture is then maintained at ambient temperature for a period from about 0.5 hours to about 3 days under an inert atmosphere.

9. The process as defined in claim 6 wherein the ethyl alcohol is employed in a molar ratio to the H2-2 dihydrate within the range from about 14:

1 to about 42;

1, and the seeds of the N-3 anhydrate crystalline form are employed in a molar ratio to the H2-2 dihydrate crystalline form within the range from about 0.001;

1 to about 0.020;

1.

10. A process for preparing the H2-1 dihydrate crystalline form of the IKur compound of the structure

as defined in claim 2, which comprises:

a) providing the IKur compound in the form of an amorphous solid, H2-1 dihydrate or H2-2 dihydrate and/or a mixture of two or more thereof;

b) optionally forming a mixture of the IKur compound in n-butyl alcohol, and concentrated hydrochloric acid;

c) mixing the IKur compound from step a) or step b) with ethyl alcohol at a reduced temperature below about 5°

C.; and

d) treating the reaction mixture from step b) or step c) with a strong base while maintaining the reaction mixture at a temperature within the range from about 0°

C. to about −

25°

C., and optionally adding trisodium phosphate to adjust pH of the reaction mixture within the range from about 6.5 to about 9, to cause precipitation of the H2-1 dihydrate.

11. The process as defined in claim 10 wherein the butyl alcohol is employed in a molar ratio to the starting IKur compound within the range from about 12:

1 to about 24;

1, and the concentrated hydrochloric acid is employed in a molar ratio to the starting IKur compound within the range from about 4;

1 to about 10;

1.

12. The process as defined in claim 10 wherein the reaction mixture from step a) is treated with ethyl alcohol employing a molar ratio of ethyl alcohol to IKur compound within the range from about 30:

1 to about 60;

1.

13. The process as defined in claim 10 wherein the reaction mixture from step b) or step c) is treated with NaOH and trisodium phosphate to adjust pH of the reaction mixture within the range from about 6 to about 7.5.

14. A process for preparing the H2-2 dihydrate crystalline form of the IKur compound of the structure

as defined in claim 3, which comprises:

a) providing an IKur compound in the form of an amorphous solid, H2-1 dihydrate, H2-2 dihydrate and/or a mixture of two or more thereof at a reduced temperature below about 2.5°

C.;

b) mixing the IKur compound from step a) with ethyl alcohol;

c) treating the reaction mixture from step b) with a base and optionally trisodium phosphate to adjust pH within the range from about 6.5 to about 9 while maintaining the reaction mixture at a temperature within the range from about 0 to about −

2.5°

C., to cause precipitation of the H2-1 dihydrate of the IKur compound and form a reaction slurry;

d) seeding the reaction slurry containing H2-1 dihydrate with crystals of H2-2 dihydrate;

e) adjusting pH of the reaction mixture from step d) or the reaction slurry from step c) within the range from about 5.5 to about 8.5; and

f) heating the reaction mixture from step e) at a temperature within the range from about 30 to about 50°

C. to form the H2-2 dihydrate.

15. The process as defined in claim 14 including the step of mixing ethyl alcohol with the reaction mixture of step a).

16. The process as defined in claim 14 including the step of seeding the reaction mixture from step c) with crystals of H2-2 dihydrate employing a molar ratio of H2-2 dihydrate:

H2-1 dihydrate within the range from about 0.001;

1 to about 0.020;

1.

17. A process for preparing the methyl t-butyl ether (MTBE) solvate crystalline form of the IKur compound of the structure

as defined in claim 5, which comprises:

a) forming a slurry of the IKur compound in MTBE; and

b) mixing the slurry from step a) with seeds of MTBE solvate to form MTBE solvate.

18. A process for preparing the H2-2 dihydrate crystalline form of the IKur compound

as defined in claim 3, which includes the steps of:

a) dissolving the IKur compound, in the form of an amorphous solid, H2-1 dihydrate, H2-2 dihydrate or a mixture of two or more thereof, in ethyl alcohol;

b) adding the solution of IKur compound to an aqueous slurry of seeds of H2-2 dihydrate crystalline form of the IKur compound to form a slurry;

c) heating the slurry from step b) at a temperature within the range from about 35°

C. to about 65°

C.;

d) optionally adding ethyl alcohol to the reaction mixture from step c);

e) optionally adding additional seeds of H2-2 dihydrate crystalline form to the reaction mixture from step c) or step d) to form H2-2 dihydrate;

f) optionally cooling the reaction mixture from step e) at a temperature within the range from about −

5 to about 10°

C.; and

g) recovering H2-2 dihydrate.

19. The process as defined in claim 18 wherein the seeds of H2-2 dihydrate are employed in a molar ratio to the starting IKur compound within the range from about 0.001:

1 to about 0.010;

1.

20. The process as defined in claim 18 wherein the reaction mixture from step c) is treated with ethyl alcohol employing a molar ratio of ethyl alcohol to IKur compound within the range from about 10:

1 to about 30;

1.

21. The process as defined in claim 18 including the step of mixing ethyl alcohol with the reaction mixture of step c).

22. The process as defined in claim 18 including the step of seeding the reaction mixture from step d) with crystals of H2-2 dihydrate employing a molar ratio of H2-2 dihydrate:

H2-1 dihydrate within the range from about 0.001;

1 to about 0.015;

1.

23. The H2-1 dihydrate crystalline form of the free base of the structure

prepared by the process as defined in claim 10.

24. The H2-2 dihydrate crystalline form of the free base of the structure

prepared by the process as defined in claim 14.

25. The N-3 anhydrate crystalline form of the free base of the structure

prepared by the process as defined in claim 6.

26. The MTBE solvate crystalline form of the free base of the structure

prepared by the process as defined in claim 17.

27. A pharmaceutical composition comprising at least one compound according to claim 1 and a pharmaceutically-acceptable carrier or diluent.

28. A pharmaceutical composition comprising at least one compound according to claim 4 and a pharmaceutically-acceptable carrier or diluent.

29. A method of treating arrhythmia disorder comprising administering to a patient in need of such treatment a pharmaceutical composition according to claim 1.

30. The method of claim 29 in which the inflammatory disorder is selected from asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, and arthritis including rheumatoid arthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, gouty arthritis and osteoarthritis.

31. The pharmaceutical composition as defined in claim 27 in the form of an oral solution comprising:

a) N-3 anhydrate, H2-1 dihydrate, H2-2 dihydrate, amorphous form or MTBE solvate;

b) d-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS);

c) polyoxyethylene (20) sorbitan monooleate;

d) ethanol; and

e) polyethylene glycol 400.

32. The composition as defined in claim 31 comprising:

N-3 anhydrate—

5 to 30 mg/mL, and a carrier comprising;

a) TPGS—

15 to 20% w/w;

b) polyoxyethylene (20) sorbitan monooleate—

7 to 10% w/w;

c) ethanol—

8 to 12% w/w; and

d) polyethylene glycol 400—

50 to 70% w/w.

33. The composition as defined in claim 32 having the following composition:

N-3 anhydrate—

30 mg/mL and a carrier comprising;

a) TPGS—

20% w/w;

b) polyoxyethylene (20) sorbitan monooleate—

8.5% w/w;

c) ethanol—

10% w/w; and

d) polyethylene glycol 400—

61.5% w/w.

34. The pharmaceutical composition as defined in claim 27 in the form of an oral suspension comprising:

a) N-3 anhydrate, H2-1 dihydrate, H2-2 dihydrate, amorphous form or MTBE solvate;

b) polyoxyethylene (20) sorbitan monooleate; and

c) purified water.

35. The composition as defined in claim 34 comprising:

N-3 anhydrate—

2 to 10 mg/mL, and a carrier comprising;

a) polyoxyethylene (20) sorbitan monooleate—

0.01 to 1% w/w; and

b) purified water—

98 to 99.95% w/w.

36. The composition as defined in claim 34 comprising:

N-3 anhydrate—

2 mg/mL, and a carrier comprising;

a) polyoxyethylene (20) sorbitan monooleate—

0.05% w/w; and

b) purified water—

99.95% w/w.